ID8: A Syngeneic Mouse Model for Testing Ovarian Cancer Immunotherapies

Ovarian cancer is an unmet medical need and particularly lethal because it is often detected only when disease is quite advanced. In 2017, approximately 22,440 women will be diagnosed with ovarian cancer in the United States, and approximately 14,080 deaths will occur. Combination platinum and anti-mitotic taxane based chemotherapy is the standard of care in […]

Sensitivity of Syngeneic Tumor Models to Focal Radiation

“Sensitivity of Syngeneic Tumor Models to Focal Radiation” Introduction and Background Use of image-guided focal irradiation is a mainstay of human cancer treatment. Image guidance allows for highly conformal treatment plans that minimize normal tissue toxicity and systemic response. With the advent of image-guided small animal irradiators such as the […]

A20: Modeling B Cell Lymphoma in Mice

Lymphomas represent a highly heterogenous set of lymphoid cell malignancies. They can originate from either B or T cells, but B cell-derived lymphomas, specifically non-Hodgkin lymphoma (NHL), are the most prevalent. Lymphomas can be diagnosed in children and adolescents, but incidence of lymphoma increases significantly with age, the median age of diagnosis being 67 years. […]

Models for Pancreatic Cancer

PANC-1 PANC-1 was isolated from a 56-year-old Caucasian man with pancreatic ductal adenocarcinoma. Subcutaneous tumor growth is reliable and consistent, with tumor volume doubling every 5 days and typically reaching evaluation size (~750mm3) in approximately 29 days post implant. Treatment with gemcitabine (160mg/kg) is well tolerated and produces statistically significant […]

Focal Radiation in the Murine 4T1-luc2 Mammary Cancer Model

The use of immuno-oncology therapies have seen remarkable progress in the last five years and are currently undergoing clinical trial use in combination with a variety of agents including radiation therapy (RT).1 RT is a main-stay in clinical oncology treatments with approximately 60 percent of cancer patients receiving RT at some point during their care. […]

Pan02 – Pancreatic Ductal Adenocarcinoma Model Characterized for Immuno-oncology Applications

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer representing about 95% of all cases. In 2017, approximately 50,987 people will be diagnosed with PDAC in the United States, and approximately 40,936 patient deaths will occur, making PDAC one of the most lethal forms of cancer. Combination anti-metabolite and anti-mitotic taxane based […]

The State of Modeling Preclinical Immuno-Oncology Pharmacology

The field of cancer immunology or immuno-oncology (I/O) dates back to the 1890’s with efforts by William Coley to treat malignancies by infection with certain bacterial strains.1 Fast forward 120 years, and we have observed the clinical success of multiple checkpoint inhibitor antibodies against cancer specific T cell negative regulatory pathways in multiple cancer types.2 […]

Preclinical Models of Multiple Myeloma

“Preclinical Models of Multiple Myeloma” Introduction and Background Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow that is invasive and drug resistant. Patients are generally asymptomatic until very late state disease. There are few preclinical models […]

MM.1S: A Model for Multiple Myeloma

Mean Total Tumor Burden BLI Signal In SCID beige mice, the median tumor volume doubling time is ~2 days (Figure 3), and median time to morbidity/mortality endpoint is 35-45 days. To further optimize the MM.1S-pMMP-LucNeo model, we characterized growth in the NSG mouse strain which shows more aggressive disease onset […]

Characterization of Proliferation in Multiple Lymphocyte Subsets in the CT26 Murine Colon Carcinoma Model by Multi-color Flow Cytometry

“Characterization of Proliferation in Multiple Lymphocyte Subsets in the CT26 Murine Colon Carcinoma Model by Multi-color Flow Cytometry” Introduction and Background: The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4, anti-PD-1, and anti-PD-L1, has altered the paradigm of cancer treatment. Subsequently, the […]

Preclinical Success to Clinical Failure: Do We Have a Model Problem or an Endpoint Problem?

As the AACR (American Association for Cancer Research) Annual Meeting is fast approaching, many industry and academic scientists are busy preparing talks and posters for what they hope will be the next new wave in cancer therapy or the next “new and improved” preclinical model. However, while these may be long shots, it’s the scientific […]